NextCure - Public Comps and Valuation Multiples

NextCure Overview

About NextCure

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer’s disease.

Founded

2015

HQ

Employees

Website

nextcure.com

Sectors

Drug Development & Therapeutics
Vaccines & Immunotherapies
BioTech

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

-$53.9M

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

NextCure Financials

NextCure has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, NextCure achieved revenue of n/a and an EBITDA of -$54.3M.

NextCure expects next 12-month revenue of XXX and NTM EBITDA of XXX

See NextCure valuation multiples based on analyst estimates

NextCure P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	n/a	n/a	XXX	XXX	XXX
Gross Profit	n/a	n/a	XXX	XXX	XXX
Gross Margin	NaN%	NaN%	XXX	XXX	XXX
EBITDA	-$64.0M	-$54.3M	XXX	XXX	XXX
EBITDA Margin	-Infinity%	-Infinity%	XXX	XXX	XXX
Net Profit	-$74.7M	-$62.7M	XXX	XXX	XXX
Net Margin	-Infinity%	-Infinity%	XXX	XXX	XXX
Net Debt	n/a	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

NextCure Stock Performance

As of April 15, 2025, NextCure's stock price is $0.

NextCure has current market cap of $8.7M, and EV of -$53.9M.

See NextCure trading valuation data

NextCure Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
-$53.9M	$8.7M	XXX	XXX	XXX	XXX	$-1.92

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

NextCure Valuation Multiples

As of April 15, 2025, NextCure has market cap of $8.7M and EV of -$53.9M.

NextCure's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate NextCure's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for NextCure and 10K+ public comps

NextCure Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	-$53.9M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	XXX	XXX
EV/EBITDA	1.0x	XXX	XXX	XXX
P/E	-0.2x	XXX	XXX	XXX
P/E/Growth	n/a	XXX	XXX	XXX
EV/FCF	1.3x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get NextCure Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

NextCure Valuation Multiples

NextCure's NTM/LTM revenue growth is n/a

NextCure's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.3M for the same period.

Over next 12 months, NextCure's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate NextCure's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for NextCure and other 10K+ public comps

NextCure Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	n/a	XXX	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	XXX	XXX	XXX
EBITDA Growth	-15%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	n/a	XXX	XXX	XXX	XXX
Revenue per Employee	n/a	XXX	XXX	XXX	XXX
Opex per Employee	$1.3M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
Opex to Revenue	n/a	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry